Cholesterol‐conjugated PEGylated PAMAM as an efficient nanocarrier for plasmid encoding interleukin‐12 immunogene delivery toward colon cancer cells. (25th December 2019)

• Record Type: Journal Article
• Authors: Pishavar, Elham; Oroojalian, Fatemeh; Ramezani, Mohammad; Hashemi, Maryam
• Is Part Of: Biotechnology progress. Volume 36:Number 3(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-12-25
• Subjects: alkyl chains -- cholesterol -- cytotoxicity -- gene delivery -- IL‐12 plasmid -- PEG -- polyamidoamine; Biotechnology -- Periodicals; Food industry and trade -- Periodicals; Bioengineering -- Periodicals; 660.6
• DOI: 10.1002/btpr.2952
• Languages: English
• ISSNs: 8756-7938

Abstract

Abstract: IL‐12 is a pleiotropic cytokine, which shows an ideal applicant for tumor immunotherapy, because of its features of creating an interconnection between innate (NK cells) and adaptive (cytotoxic T lymphocyte) immunity. IL‐12 gene therapy is a useful technique to deliver an immune‐modulatory gene directly into tumor site thereby limiting the adverse effects of systemic administration of IL‐12 proteins. One of the most largely investigated non‐viral gene carriers is polyamidoamine (PAMAM). In the current research, 5 and 3% of PAMAM primary amines were substituted to transmit the plasmid encoding IL‐12 gene to cells by cholesteryl chloroformate and alkyl‐PEG, respectively. The features of modified PAMAMs containing size and surface charge density, cytotoxicity, and transfection efficiency were investigated in colon cancer cells. in vitro experiment showed that this modified carrier with average size of about 160 nm and zeta potential of 30 mV was able to increase the level of IL‐12 production up to two folds as compared to that of the unmodified PAMAM. Improvement of the polymer hydrophobic balance along with of the modulation of the surface positive charge could provide an efficient and safe non‐viral IL‐12 gene for colon cancer immunogene therapy.